Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta Protocol Changes Could Impact Future Duchenne Trials

May 21 2017

• By Sue Sutter

FDA entrance sign 2016

Related Content

Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs

Apr 24 2017

Sarepta’s ESSENCE Trial Gets FDA Panel Nod For Protocol Changes

May 19 2017

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

United States Advisory Committees Clinical Trials Pediatrics Rare Diseases FDA Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window